Drug intelligence / Profile preview

atazanavir + DNP401

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

**Atazanavir + DNP401** is a proposed combination of atazanavir, a small molecule protease inhibitor that binds to the active site of HIV-1 protease to prevent viral polyprotein cleavage and maturation, with DNP401, an investigational compound whose identity and role in this pairing are unclear from available data. Atazanavir is typically boosted with ritonavir for HIV-1 treatment, but no clinical trials, approvals, or established pharmacology exist for this specific atazanavir + DNP401 pairing, suggesting it may be experimental, hypothetical, or erroneous.

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on atazanavir + DNP401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atazanavir + DNP401.

Explore the full profile